Glucose News and Research

RSS

UCLA researchers find no evidence of association between iron levels and atherosclerosis risk

A UCLA research team has found no evidence of an association between iron levels in the body and the risk of atherosclerosis, the hardening and narrowing of the arteries that leads to cardiovascular disease, the No. 1 killer in the U.S.

18 Dec 2013

Diabetes blamed for brain neurochemical abnormalities in bipolar disorder

Diabetes may underlie some of the neurochemical abnormalities observed in the brains of patients with bipolar disorder, say researchers.

17 Dec 2013

Scientists identify protein complex essential for jumpstarting immune response during infection

St. Jude Children's Research Hospital scientists have identified a protein complex that is essential for jumpstarting the immune response during the critical first 24 hours of an infection. The research appears in the current issue of the scientific journal Immunity.

17 Dec 2013

Study explores how blood sugar levels during pregnancy influence children’s fat

Researchers from Manchester have begun a new study to determine whether blood sugar levels during pregnancy, lower than the level used to diagnose gestational diabetes, influences later levels of body fat in children and development of diabetes in mothers after giving birth.

16 Dec 2013

Low vitamin D a consequence not a cause of ill health

Low vitamin D status is a marker of ill health rather than an underlying cause of disease, say the authors of a systematic review published in The Lancet Diabetes and Endocrinology.

16 Dec 2013

MicroBiome Therapeutics announces completion of $1.3M bridge financing

MicroBiome TherapeuticsTM LLC, today announced completion of a $1.3 million bridge financing. It is intended to support completion of the company's two ongoing clinical studies and preparations for further clinical trials of lead product NM504, a microbiome modulator in development for type 2 diabetes and prediabetes. The bridge financing was led by current investor BVM Capital, who was joined in the round by other existing MBT investors.

16 Dec 2013

Janssen receives complete response letter for canagliflozin/metformin FDC therapy for type 2 diabetes

Janssen Research & Development, LLC (Janssen) today announced it has received from the U.S. Food and Drug Administration (FDA) a complete response letter regarding its New Drug Application (NDA) for a fixed-dose combination (FDC) of canagliflozin and immediate-release metformin to treat adults with type 2 diabetes.

16 Dec 2013

New approach for combating seasonal flu

Reducing glucose metabolism dials down influenza viral infection in laboratory cell cultures, providing an entirely new approach for combating seasonal flu, according to research that will be presented on Sunday, Dec. 15, at the American Society for Cell Biology annual meeting in New Orleans.

15 Dec 2013

Children can reap positive health benefits from increased physical activity

Studies conducted by the Appalachian State University Human Performance Laboratory at the NC Research Campus in Kannapolis, N.C., show that when children increase their level of physical activity, they experience positive health benefits quickly.

13 Dec 2013

Artificial sweetener sucralose has biological effects

The artificial sweetener sucralose is a biologically active compound according to an extensive review published by Taylor & Francis in the recent issue of Journal of Toxicology and Environmental Health, Part B: Critical Reviews. "Sucralose, A Synthetic Organochlorine Sweetener: Overview Of Biological Issues" authored by Susan S. Schiffman, PhD, an internationally known sweetener researcher and Kristina I. Rother, MD, MHSc, of the National Institutes of Health (NIH), summarizes the biological properties of sucralose based on hundreds of archival, peer-reviewed scientific journal publications.

13 Dec 2013

Drugs to treat type 2 diabetes may have different effects on hearts of men and women

Widely used treatments for type 2 diabetes have different effects on the hearts of men and women, even as the drugs control blood sugar equally well in both sexes, according to researchers at Washington University School of Medicine in St. Louis.

13 Dec 2013

Market research report on global and China insulin industry

As the third largest human health disease following neoplastic disease, cardiovascular and cerebrovascular diseases, the number of diabetic patients has continued growing from 246 million in 2007 to 382 million in 2013 at a compound annual growth rate of 7.6%.

12 Dec 2013

Study shows that age and sleep deprivation induce cellular stress in pancreas

Sleep, or the lack of it, seems to affect just about every aspect of human physiology. Yet, the molecular pathways through which sleep deprivation wreaks its detrimental effects on the body remain poorly understood.

12 Dec 2013

Lund University researcher explores why type 2 diabetes raises dementia risk later in life

It is well known that type 2 diabetes raises the risk of dementia. The reasons for this are less clear, but one explanation could be insulin resistance in the brain, according to Malin Wennstr-m, a researcher at Lund University's Molecular Memory Research Unit. She has received EUR 700,000 from the Swedish Research Council to investigate her theory.

12 Dec 2013

Echo Therapeutics signs strategic collaboration agreement with MTIA

Echo Therapeutics, Inc., a medical device company developing its Symphony CGM System as a non-invasive, wireless continuous glucose monitoring system, today announced that it entered into a strategic collaboration agreement with Medical Technologies Innovation Asia, Ltd., Hong Kong, for a license arrangement and equity investment in Echo.

10 Dec 2013

COC launches first clinic on London's Harley Street for specialised cancer treatment

Care Oncology Clinic, an independent, private organisation providing oncology treatments, announces today the launch of its first clinic on London's Harley Street. Delivered by leading oncologists and palliative care doctors, the clinic is the first of its kind, specifically set up to offer a specialised cancer treatment by targeting the energy requirements of cancer cells using existing medicines that are already licensed for this purpose, have an acceptable safety profile and are low cost. Designed for patients for whom the standard oncology treatment regime is not available, viable, tolerable or providing benefit, this is a new option for treating these cancer patients.

10 Dec 2013

Glucose News and Research

UCLA researchers find no evidence of association between iron levels and atherosclerosis risk

Diabetes blamed for brain neurochemical abnormalities in bipolar disorder

Scientists identify protein complex essential for jumpstarting immune response during infection

Study explores how blood sugar levels during pregnancy influence children’s fat

Low vitamin D a consequence not a cause of ill health

MicroBiome Therapeutics announces completion of $1.3M bridge financing

Janssen receives complete response letter for canagliflozin/metformin FDC therapy for type 2 diabetes

New approach for combating seasonal flu

Children can reap positive health benefits from increased physical activity

Artificial sweetener sucralose has biological effects

Drugs to treat type 2 diabetes may have different effects on hearts of men and women

Market research report on global and China insulin industry

Study shows that age and sleep deprivation induce cellular stress in pancreas

Lund University researcher explores why type 2 diabetes raises dementia risk later in life

Echo Therapeutics signs strategic collaboration agreement with MTIA

COC launches first clinic on London's Harley Street for specialised cancer treatment

Genetic deficiency in males can trigger hepatocellular carcinoma, type 2 diabetes

PKM2 protein controls mitosis, saving cancer cells from death and promoting brain tumor growth

Hummingbirds able to switch from burning glucose to fructose equally, say researchers

Professor investigates how residential environment factors may be linked to weight

Industry Focus eBook - Forensics & toxicology (2nd edition) eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News